Medical Devices - Winnipeg, Manitoba, Canada
We have designed a novel total consumption inhaler that can generate an aerosol that all its droplets are within 2 to 5 microns. This is the particle size needed to allow the drug to penetrate into the lungs for proper absorption. The current inhalers generate a wide range of droplet sizes. Therefore, most of the drug get collected in the mouth and does not enter into the lungs. This results in a significant loss of the drug and lack of knowledge of the exact dosage received by the user. As the drugs become more and more expensive, a total consumption inhaler becomes of importance. In addition, since it is not clear how of the drug actually penetrates into the lungs, the user does not know the exact drug dosage. The present total consumption inhaler allows one to know the exact amount of the drug dosage, since all of the drug that is formed into an aerosol enters the lungs. Asthma is one of the most common chronic diseases in the world, about 10% of the population in world has asthma. Asthma stands for nearly 1% of the total medical expenses in the world and untreated asthma leads to unnecessary hospital visits for the asthmatic. Untreated asthma limits the ability to live an active life, still many asthmatics do not have the level of control over their asthma as they could have. A contributing factor is improper drug delivery to the patient's lungs. Asthma is normally treated by inhaling long-term control medicine (controller) and quick-relief medicines (reliever) or a combination of both medication (combination medication) from asthma inhalers. The inhaled route remains crucial for the treatment of bronchial diseases. However, drug deposition and subsequent treatment effectiveness are highly dependent on inhalation technique, which is incorrect in many patients with asthma and COPD. Many inhalation devices are available and others are currently being developed with the aim of simplifying required handling, and thus improving treatment safety.